Page 2 - These Phase News Today

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTST...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ... Santhera Pharmaceuticals Holding AGApril 28, 2021 GMT Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term tre...

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy se in , - y with other steroids . A sequence of studies investigated the safety, tolerability and long-term treatment benefit with vamorolone and provide open-label data in a total of 46 patients with DMD, aged 4 to up to 10 years (start/end of treatment), of which 41 (89%) completed a 2.5 years treatment period. 48 participants initially completed a ...

Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years in decline for time to stand (TTST...

Regeneron asks FDA to approve use of its COVID-19 cocktail that Trump hailed as ‘key’ to his recovery as preventative measure after trial showed it cut the risk of symptomatic infection by up to 76% Regenerons cocktail, a mixture of two drugs, imitates antibodies that the body generates when fighting the coronavirus in order to boost the immune system The antibody treatment was authorized by the FDA to treat mild to moderate cases of COVID-19 in November  It was given to former President D...

DHEC launches program to vaccinate homebound residents By WIS News 10 Staff | February 25, 2021 at 5:20 PM EST - Updated February 27 at 3:17 PM COLUMBIA, S.C. (WIS) - DHEC has announced it will be partnering with Agape Care Group to help bring COVID-19 vaccines to homebound Phase 1a individuals in Hampton and Jasper Counties. As part of ongoing efforts to ensure all South Carolinians have equal and fair access to COVID-19 vaccines, DHEC has been developing plans to ensure individuals who m...

Operator Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2020 earnings conference call. [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. Liz Shea -- Vice President of Investor Relations Good morning, and thanks for joining us. Also on the call with me today are Rick Gonzalez, chairman of the board and chief executive officer; Michael Severino, vice chairman and president; and Rob Michael, executive vice p...